Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies-Reference-Cited by-同舟云学术

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

Published:2021-09-13 Issue:6 Volume:2 Page:568-576
ISSN:2643-3230
Container-title:Blood Cancer Discovery
language:en
Short-container-title:Blood Cancer Discov

Author:

Chung David J.^ORCID,Shah Gunjan L.^ORCID,Devlin Sean M.,Ramanathan Lakshmi V.,Doddi Sital,Pessin Melissa S.^ORCID,Hoover Elizabeth,Marcello LeeAnn T.^ORCID,Young Jennifer C.,Boutemine Sawsan R.,Serrano Edith,Sharan Saumya,Momotaj Saddia,Margetich Lauren,Bravo Christina D.,Papanicolaou Genovefa A.,Kamboj Mini,Mato Anthony R.,Roeker Lindsey E.,Hultcrantz Malin,Mailankody Sham,Lesokhin Alexander M.,Vardhana Santosha A.^ORCID,Knorr David A.

Funder

The Society of Memorial Sloan Kettering

NIH

NCI

Leukemia and Lymphoma Society

Pershing Square Sohn Cancer Research Alliance

Conrad Hilton Foundation

NCI Cancer Center Support

Publisher

American Association for Cancer Research (AACR)

Subject

General Medicine

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation;Blood Advances;2023-12-29

2. Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination;Expert Review of Vaccines;2023-11-10

3. COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study;Vaccines;2023-10-30

4. Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients;Clinical and Experimental Medicine;2023-10-28

5. Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies;Cancer Medicine;2023-07-06